drugset / Trial / NCT05744115
Ga-68-PSMA-11 in Men With Prostate Cancer
Phase 3
Terminated
38 enrolled
Timothy Hoffman
Harry S. Truman Memorial Veterans' Hospital · collabTelix Pharmaceuticals (Innovations) Pty Limited · collabUniversity of Missouri-Columbia · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to provide access to Ga-68-PSMA-11 PET for evaluation of male veterans with newly diagnosed or biochemically recurrent prostate cancer. All patients will receive conventional imaging (MRI, CT, and/or a molecular imaging bone scan) as well as Ga-68-PSMA-11 PET in order to evaluate the utility of diagnostic testing in patients with positive PSA status, a comparison of results from conventional imaging and PSMA PET imagining will be performed.
Timeline
- Start
- 2021-07-27
- Primary completion
- 2022-04-14
- Completion
- 2022-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 259 mbq | Intravenous |